Login
Companies $HSDT
$1.64 +$0.00 (0.0%) After hours

What Do They Do?

Acquires and holds Solana tokens for public-market investors, and sells a tongue-stimulation device and therapy for patients with gait or balance problems.

How Do They Make Money?

Patients, the U.S. e-commerce partner and Canadian clinics pay for PoNS products, with some U.S. customers paying before shipment; validator arrangements provide SOL staking rewards as the company makes SOL available over time.

revenue
SegmentShareRevenue
Product
Sold outright

77%
Other revenue
Recurring

23%

Who Are Their Customers?

PoNS products are sold directly to patients and clinics in Canada, and through a U.S. e-commerce partner.

Do Revenues Turn Into Profits?

No. It lost $40.9M in FY2025.

Operating income, FY2025
−4053% of revenue
▼ −1654% (Loss) vs FY2024 (−$13.9M, −2674%)
Net income, FY2025
−680% of revenue
▼ −248% (Loss) vs FY2024 (−$11.7M, −2258%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +382%
vs $697K in Q3 FY2025
Net income
▲ Turned profitable
vs −$352.8M in Q3 FY2025

Growing. Revenue grew 11.5x in 4 years, from $522K in FY2021 to $6M in FY2025, about 84% a year.

A new treasury focus The business has shifted from a neurotechnology company focused on developing technologies for neurological conditions to a digital-asset treasury focused on acquiring and holding Solana tokens, while retaining neurotechnology operations as a secondary business.

Revenue over time
Product Other revenue License
$1M$500K$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support